Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · IEX Real-Time Price · USD
19.42
-0.04 (-0.21%)
Jul 1, 2022 1:15 PM EDT - Market open
Company Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 144 |
Contact Details
Address:
950 Tower Lane Foster City, CA 94404 United States | |
| Phone | 650 667 4085 |
| Website | mirumpharma.com |
Stock Details
| Ticker Symbol | MIRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $15.00 |
| CIK Code | 1759425 |
| CUSIP Number | 604749101 |
| ISIN Number | US6047491013 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Peetz | President, Chief Executive Officer and Director |
| Dr. Ian Clements | Chief Financial Officer |
| Peter Radovich M.B.A., Ph.D. | Chief Operating Officer |
| Paul K. Ross | Chief Compliance Officer |
| Erin Campany | Senior Vice President of Human Resources |
| Dr. Pamela Vig Ph.D. | Head of Research & Development |
| Lara Longpre MBA, MSC | Chief Development Officer |
| Vinita P. Kumar | Senior vice President of Quality |
| Saira Gonsalves Ramasastry M.S. | Managing Partner of Life Sciences Advisory, LLC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2022 | EFFECT | Notice of Effectiveness |
| Jun 8, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 7, 2022 | 3 | Initial statement of beneficial ownership of securities |
| Jun 6, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 6, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 6, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 6, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 6, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 6, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 6, 2022 | 4 | Statement of changes in beneficial ownership of securities |